Although first-time miscarriages are usually caused by chromosomal defects, about 55% of recurrent miscarriages are caused by procoagulant defects that induce thrombosis and infarction of placental vessels. Of recurrent miscarriages, about 7% are caused by chromosome defects, 15% to hormonal defects, and 10% to 15% to anatomical defects. Recurrent miscarriage involves more than 500,000 women in the United States each year. During the past 4 years, 179 patients, prescreened for chromosomal, hormonal, and anatomical defects, and found to harbor none, underwent hemostasis defect evaluation. A total of 160 of these have been analyzed. A hemostasis defect was found in 150 of 160 women ( n = 94% of screened women). The mean age was 33 years; the mean number of
miscarriages before referral was three. All women with a procoagulant defect (149) were treated with preconception ASA at 81 mg/d, and unfractionated porcine heparin at 5000 U every 12 hours was added immediately postconception; both agents were used to term delivery. Only two of 149 patients failed therapy. The defects found were as follows: antiphospholipid syndrome, 67%; sticky platelet syndrome, 21 %; tissue plasminogen activator (TPA) deficiency, 9%; factor V Leiden, 7%; high PAI-1, 6%; protein S, 5%; high LP(a), 3%; AT, 2%; protein C, 1%. Thirty-eight patients had more than one defect. In the group with antiphospholipid syndrome, 24% only had a subgroup antibody (antiphosphatidyl-serine, -inositol, -ethanolamine, -choline, -glycerol) or antiphosphatidic acid antibody, in the absence of anticardiolipin antibody or lupus anticoagulant. This finding is similar to that recently reported in early age ischemic stroke patients (<50 years old).
In summary, about 55% of patients with recurrent miscarriage harbor a procoagulant defect to account for placental vascular occlusion. More than 98% will have a normal term delivery with preconception aspirin (ASA) and addition of postconception heparin to term. Patients should be screened by an obstetrician or by reproductive specialists for hormonal and anatomic defects before initiating a procoagulant evaluation; if such prescreening is done, the yield of a defect is high and appropriate therapy leads to an excellent outcome. Recurrent miscarriage syndrome (RMS) is a common obstetrical problem, affecting more than 500,000 women per year (1) . Infertility, although less well defined in the population, is also a common clinical problem (1) . Recurrent miscarriage, based upon literature available (1) and our experience, is generally caused by well defined defects as follows: about 7% are secondary to chromosomal abnormalities, about 10% are due to anatomical abnormalities, about 15% appear to be caused by hormonal abnormalities (progesterone, estrogens, diabetes, or thyroid disease), about 6% cannot be explained, and the remainder, about 55 to 62%, are caused by blood coagulation protein or platelet defects ( 1 ) . The approximate prevalence of causes of RMS and infertility are summarized in Figure 1 ( 1 ) . This is in contrast to first time miscarriage, in which about 90% of cases are caused by chromosomal defects and may affect up to 25% of first time pregnancies (1).
FIG. 1. Defects causing recurrent miscarriage (approximate). We (2) published our initial experience in 1995, presenting 46 patients with RMS caused by procoagulant or platelet defects; herein is presented an additional 160 consecutive patients. Prevalence of defects, treatment used, and outcome is also presented and discussed.
MATERIALS AND METHODS

Patient population
During the past 4 years, we have carefully assessed 179 women with RMS. In the Dallas/Fort Worth Metroplex (DFW Metroplex), comprised of a population of about 6 million, a flow protocol is followed to maximize success and keep costs of evaluation for etiology of RMS/infertility at a minimum, although providing the best changes for defining an etiology and, thus, poten-tially contributing ideal therapy for successful term pregnancy outcome. This protocol is presented in Figure 2 . In all instances, the women with RMS/infertility are first seen by an obstetrician or reproductive specialist. At this stage, anatomical defects and hormonal defects are assessed and, if found, the workup stops at this point and treatment is initiated (about 25% of all women). If no anatomical or hormonal defect is found, the patient is then seen for hemostasis evaluation; the positive yield among this selected population is about 94%. If this evaluation is negative (about 6%) and if the patient desires, chromosomal evaluation is initiated (about a 7% yield). Most of the obstetricians or reproductive specialists in the DFW Metroplex refer after two or more miscarriages. However, some refer after one miscarriage in the face of a positive family history for miscarriage, and, occasionally, patients will request a workup after only one miscarriage. Our practice has been to accommodate the desires of the patient after discussing the costs and other implications of evaluation. The first 160 of the 179 patients referred have been analyzed in detail and the resultant data are herein presented.
Laboratory evaluation
In order to contain costs of evaluation, patients are given options of being evaluated at one time or to be evaluated in two stages, to contain costs; stage I consists of more common hemostasis defects associated with RMS, and stage II consists of less common hemostasis FIG. 2. Recurrent miscarriage program DFW metroplex referral protocol. defects associated with RMS. Most women, when given the choice, wish to undergo complete evaluation at first visit. Stage I consists of a complete history and physical examination, a routine complete blood and platelet count (CBC-P), and a panel of those blood protein or platelet defects thought to be most commonly associated with RMS. If the first panel of blood protein or platelet defect tests are normal, a second panel (Stage II), consisting of those blood protein defects thought to be less commonly associated with RMS, is initiated.
The blood protein or platelet defect assays performed in panel I consisted of: prothrombin time and activated partial thromboplastin time (aPTT) by routine techniques (3) on the ACL 3000; anticardiolipin antibodies (IgG, IgA and IgM idiotypes) by solid phase enzyme-linked immunospecific assay (ELISA) (4); lupus anticoagulant (with phospholipid confirmation if positive) by the dilute Russell's viper venom time (dRVVT) assay (5-7); antiphospholipid subgroups, consisting of antiphosphatidylserine (IgG, IgA, and IgM), antiphosphatidylethanolamine (IgG, IgA, and IgM), antiphosphatidylinositol (IgG, IgA, and IgM), antiphosphatidylcholine (IgG, IgA, and IgM), antiphosphatidylglycerol (IgG, IgA, and IgM), and antiphosphatidic acid (IgG, IgA, and IgM); by methods described by Toschi (8) ; P-2-glycoprotein-I (9); hexagonal phospholipid (10) ; functional protein S (11), followed by a protein S panel of immunological (total) (12) and free protein S (13) and C4b-binding protein (14) if the functional protein S level is abnormally low; Protein C assay by chromogenic technique (15) ; Factor XIII by immunoassay (16) and function (17) ; antithrombin assay by chromogenic technique (18) ; sticky platelet syndrome (SPS) assay by the method of Mammen (19); activated protein C resistance (APC-R) by the method of Dahlback (20); Factor V Leiden by PCR by the method of Dahlback (21); and functional fibrinogen assay by the method of Clauss (22). If all of these are negative, the secondary panel consists of: plasminogen assay by chromogenic assay (23); plasminogen activator inhibitor Type 1 (PAI-1 ) (24); tissue plasminogen activator (t-PA) (25); heparin cofactor II (26); tissue factor pathway inhibitor (TFPI) (27); prothrombin gene G20210A mutation by the method of Poort (28); methylenetetrahydrofolate reductase (MTHFR) C677T mutation (29); and fasting blood homocysteine levels (30). All abnormal results, except polymerase chain reaction (PCR) results, were repeated at least once for confirmation. Plasma heparin levels, for those patients placed on heparin, were done by anti-Xa assay (31).
Treatment regimen
All patients found to have a blood protein or platelet defect associated with fetal wastage syndrome via hypercoagulability and thrombosis (thrombosis/vasculitis) of placental vessels were treated with preconception low dose aspirin (ASA) at 81 mg/d. The ASA was started immediately upon (1) making a diagnosis of fetal wastage syndrome, (2) associated with a blood protein/ platelet defect known to be associated with thrombosis and RMS, and (3) a desire for pregnancy. Immediately postconception, fixed low dose subcutaneous heparin at 5000 U (anti-Xa) every 12 hours was added to the daily ASA regimen. The heparin used was Fuji porcine mucosal heparin (20,000 U/mL concentration). Both drugs were used to term. All patients are instructed in proper methods for self-administration of subcutaneous heparin injections, informed of all important side effects of heparin therapy, and extensively informed of the benefits and risks of heparin therapy, including the fact that side effects, although rare, include heparin-induced thrombocytopenia (HIT) with and without paradoxical thrombosis or thromboembolism (HITT); osteoporosis; mild to moderate alopecia; skin and allergic reactions, including erythema and itching, at injection sites; eosinophilia (of little consequence;) and potential bleeding (32, 33) . Patients are also informed that about 5 to 10% of patients develop a transient transaminasemia during heparin therapy, but this is without any known adverse clinical consequences (34). Patients are also instructed that the ideal injection sites are the anterior or lateral thighs; that injection sites should be rotated with every injection; that each injection is likely to produce a bruise about 0.5 cm. to 4.0 cm in diameter; and pain of injection, if experienced, can usually be alleviated by applying a small piece of ice at the site for 20 seconds before and 20 seconds after the injection is given. All patients are instructed to return immediately if they note dark or black areas of the injection site, potentially indicative of skin necrosis. The methods of follow-up are summarized in Table 1 .
Patients with hypercoagulability defects were usually encouraged to continue the use of ASA indefinitely, following delivery, depending upon defect(s) found.
RESULTS
The mean age of patients referred for a hemostasis evaluation was 32.9, the mean number of miscarriages before referral was 2.73, and the percent found with a hemostasis defect was 94%. This information is provided in Table 2 .
At least one procoagulant defect was found in 149 patients; one had Factor XIII deficiency; thus, 150 of 160 patients (93.7%) of this appropriately and sequentially selected population had a hemostasis defect. The most common defect found was antiphospholipid syndrome (67.3% of all defects found), followed by sticky platelet syndrome (SPS; 20.6% of all defects found), followed by ASA, preconception aspirin; CBC, complete blood count; PO, orally. tissue plasminogen activator (tPA) defects (8.8%), followed by factor V Leiden (6.9%), PAI-1 defects (5.6%), and others. It is of interest that by including all antiphospholipid subgroups, it is found that 24% of patients have only a &dquo;subgroup&dquo; antiphospholipid antibody, but no anticardiolipin antibody or lupus anticoagulant; thus, 24% of patients would remain undiagnosed if these subgroups are not performed. Interestingly, this is about the same finding recently noted in young age (< 51 years) thrombotic stroke patients (8) . The hemostasis defects found in our population are summarized in Table 3 . The particulars of the antiphospholipid patients, with demonstration of the idiotypes found, are summarized in Table 4 .
All patients (except one with Factor XIII deficiency) were treated with preconception aspirin at 81 mg/d, and, at documentation of conception, were treated with the addition of subcutaneous unfractionated porcine mucosal heparin at 5000 U every 12 hours by self-injection. Both drugs are used to term.
OUTCOMES
Of the 150 patients with a defect, 149 (exclusive of the patient with Factor XIII deficiency) were treated with the aforementioned regimen of preconception low dose ASA plus addition of postconception low dose subcutaneous porcine heparin. There were a total of four losses (2.6%); only two were treatment failures. One loss was during the second trimester and accompanied a cholycystectomy, and one loss was during the first trimester in an individual with antiphospholipid syndrome (APLS) whose baby had a fetal chromosomal defect; these were not considered treatment (ASA + heparin) failures. However, two patients suffered loss on ASA plus heparin, and placental thrombi and infarcts were present; thus, there were two losses that clearly represented treatment failure. The overall success in treating RMS patients with procoagulant or platelet defects in our program is, therefore, 147 of 149 (98.6%) with respect to normal term delivery.
DISCUSSION
Blood coagulation protein and platelet defects
Recurrent miscarriage syndrome (RMS) caused by blood protein or platelet defects may come about through two mechanisms, those disorders associated with a hemorrhagic tendency or those defects associated with a thrombotic tendency. Hemorrhagic (bleeding) defects associated with RMS are very rare, whereas thrombotic or hypercoagulable defects are extremely common (1, 2) . The hemorrhagic defects associated with fetal wastage syndrome presumably lead to inadequate fibrin formation, thus precluding adequate implantation of the fertilized ovum into the uterus. The hemorrhagic defects associated with fetal wastage syndrome include Factor XIII deficiency (35); Factor X deficiency (36); Factor VII deficiency (37); Factor V deficiency (38); Factor II (prothrombin) deficiency (39); von Willebrand's syndrome; carriers of Hemophilia and fibrinogen defects, including afibrinogenemia (40); and those dysfibrinogenemias associated with hemorrhage (41). Management of these patients is generally plasma substitution therapy or, in appropriate disorders, DDAVP therapy (1, 2) .
The thrombotic defects associated with fetal wastage are thought to occur because of thrombosis of early placental vessels, with peak fetal wastage in the first trimester ; but small peaks also occur in the second and third trimesters (1, 2) . It appears the earlier the pregnancy, the smaller the placental and uterine vessels, and the greater the propensity to undergo partial or total occlusion by thrombus formation. Thrombotic occlusion of placental vessels, both venous and arterial, preclude nutrition and, thus, viability of the fetus (1, 2) .
The thrombotic hemostasis defects associated with RMS include lupus anticoagulants and anticardiolipin antibodies (these two comprising the antiphospholipid syndromes associated with fetal wastage syndrome) (42-44) ; Factor XII deficiency (45); dysfibrinogenemias associated with thrombosis (46); protein C deficiency (47); protein S defects; antithrombin deficiency (48); heparin cofactor II deficiency (49); and fibrinolytic defects associated with thrombosis, including plasminogen deficiency ; tissue plasminogen activator (t-PA) deficiency; and elevated plasminogen activator inhibitor Type 1 (PAI-1) (50,51), including PAI-1 polymorphisms (52). Also, although sticky platelet syndrome has been known for more than a decade and leads to a wide variety of arterial and venous events, only recently has it become apparent that this defect is a common cause of RMS (2,53), and, like other new defects, including factor V Leiden, 5,10-MTHFR mutations and prothrombin G20210A gene mutation, it should be added to the prothrombotic disorders associated with RMS (2). It is anticipated that as new procoagulant factor mutations associated with hypercoagulability and thrombosis are discovered, they too will be found associated with placental thrombosis and RMS in many cases. We only recently have added prothrombin gene G20210A mutation and 5,10-MTHFR C677T mutation to our RMS panels; however, of the last 19 patients seen (not included in this analysis) we have already seen two cases of RMS caused by MTHFR mutation and one caused by prothrombin G20210A mutation.
Procoagulant defects
The antiphospholipid syndrome has clearly been the most common thrombotic defect leading to fetal wastage syndrome, and a variety of treatment programs have been advocated. One difficulty in evaluating these has been that some populations have addressed primarily patients with secondary antiphospholipid syndrome and fetal wastage-in particular, those with underlying systemic lupus erythematosus or other autoimmune disordersand only a few investigators have addressed populations with primary antiphospholipid syndrome with no known underlying disease. Like that found by most other investigators, discussed previously, the most common defect found has been APLS. However, unlike some groups, we assess for all phospholipid antibody subgroups, including antiphosphatidylserine; antiphosphatidylethanolamine; antiphosphatidylglycerol; antiphosphatidic acid; antiphosphatidylcholine ; antiphosphatidylinositol; ~-2-Glycoprotein-1 ; hexagonal phospholipid; and lupus anticoagulant (by dRVVT, with correction by nonplatelet-derived phospholipid to avoid false positive results). We always assess all three idiotypes of anticardiolipin antibody (IgG, IgA and IgM); however, an incomplete evaluation continues to be made by many who evaluate these patients and leave out either IgA or IgM idiotypes. Table 5 summarizes the bleeding disorders that may give rise to RMS or infertility; it should be appreciated these are very rare causes as compared with prothrombotic disorders. Table 6 summarizes the hypercoagulable, prothrombotic disorders leading to, or potentially leading to, RMS or infertility by inducing placental or uterine arterial or venous thrombosis; these defects are common causes of RMS and infertility.
Antiphospholipid Syndrome (APLS) has long been recognized as a cause of miscarriage and infertility, and that treatment is often successful (36). Many clinicians consider APLS to be the most common prothrombotic disorder among both hereditary and acquired defects and the most common thrombotic disorder causing recurrent miscarriage (1, 2, 42, 43, (54) (55) (56) (57) (58) . When assessing causes of infertility alone, APLS is thought to account for about 30% of infertility; however, in one series, abnormal CD 56+ or CD 16-cell ratios were the single most common defect found (40%) in infertility patients (59) . In another recent series, only 21 % of patients with RMS had APLS; however, when assessing women with APLS historically, 80% had suffered at least one miscarriage (60) . In a series reported by Granger (61) , 384 unselected patients were assessed for APLS; of these, 16% harbored APLS, and of those with APLS, 56% had a term delivery with low dose ASA. Borelli (62) found that 60% of patients with &dquo;habitual&dquo; unexplained miscarriage harbored APLS. Although the great majority of cases of APLS are clearly acquired (56, 57) , familial APLS associated with RMS has been reported (63) . Clearly, however, screening for APLS is indicated in patients with RMS (1, 2, 42, 43, (54) (55) (56) (57) (58) 63) . The reason our percentage is so high is most likely because (1) all antiphospholipid antibodies are measured, and (2) only patients in whom anatomical and hormonal defects are first ruled out are assessed. One recent study (64) has suggested that monitoring miscarriage patients with APLS by use of prothrombin Fragment 1.2 may predict preclinical placental thrombi. If this is confirmed, it may preclude the neces- APC, activated protein C; MTHFR, methylenetetrahydrofolate reductase ; PAI-1, plasminogen activator inhibitor type 1; TPA, tissue plasminogen activator. sity of frequent sonograms, which are the current mode of carefully following pregnant RMS patients on therapy.
In addition, because APLS is so common, and because many of the hereditary thrombophilias, such as Factor V Leiden, are so prevalent in North America, it is not unexpected that some women with RMS will harbor APLS in combination with other procoagulant defects. Aznar (65) has reported a case of RMS, complicated by DVT and thrombotic stroke in a patient with APLS, factor V Leiden, and congenital protein S deficiency. Many proposed mechanisms whereby APLS interferes with the hemostasis system and predispose to thrombosis have been proposed. These are summarized in appropriate ref- erences (1, 2, 42, 43, (54) (55) (56) (57) (58) 63) . However, some investigators have proposed mechanisms specific for RMS. These proposed mechanisms have included the proposal the APLS induce acquired activated protein C resistance (APC-R) (66); interference with prothrombin (Factor II); protein C and protein S; tissue factor and factor XI (67); and the tissue factor and tissue factor pathway inhibitor (TF/TFPI) system (68) . Another study (69) also found that patients with APLS also harbored antibodies to prothrombin, protein C, and protein S. Others (70) have proposed these patients may also develop antibodies to &dquo;thromboplastin&dquo; and thrombin. Another proposal (71 ) is that antiphospholipid antibodies interfere with Annexin-V (also referred to as &dquo;placental anticoagulant pro-tein&dquo;). Several studies (71-73) have shown Ig fractions of antiphospholipid antibody (APLA) or (3-2-glycoprotein-I (APLA) decrease trophoblastic Annexin-V, but several (74, 75) have shown this anti-Annexin-V activity to be limited to the antiphosphatidylserine subgroup antibody idiotype. However, two carefully done studies (76, 77) have failed to demonstrate abnormalities of Annexin-V in miscarriage patients with APLS and have concluded it plays no role in RMS. In an additional study (78) of lupus patients, anti-annexin antibodies were detected in only 19%; however, these were not miscarriage patients. In yet another study (79) , patients with thrombosis and APLS were assessed; only 8% harbored ~-2glycoprotein-1. Testing for an antiphospholipid subgroup, in this case antiphosphatidylserine, was found useful in one study in which RMS patients tested negative for lupus anticoagulants and anticardiolipin antibodies ; in this study (80) , it was thought useful to test for this subgroup. In another study (81) , however, the use of APL subgroup testing was not considered helpful. It should be noted that on rare occasions, antiphospholipid syndrome may be inherited (this author has seen three such families) and others have been reported (63) , suggesting that a positive maternal history may warrant evaluation at first pregnancy, as should a history of familial thrombosis.
Patients harboring other congenital or acquired thrombophilic states are also at high risk for placental thrombosis and RMS. In one study (2) assessing a variety of these defects in 46 selected women with RMS (anatomic and hormone defects ruled out before hemostasis assessment), the following were found: 76% had anticardiolipin antibodies (void of lupus anticoagulants); 3% had a lupus anticoagulant (void of anticardiolipin antibodies); 11 % had congenital protein S deficiency (three quantitative and one dysfunctional); 6.5% had &dquo;sticky platelet syndrome&dquo; (two with type I and one with type II); 3% had dysfibrinogenemia; and 3% had congenital tPA deficiency. In a study (82) assessing prevalence of hereditary and acquired defects in RMS patients, 9% had isolated Factor XII deficiency; 7.4% had antiphospholipid syndrome; and fibrinolytic system defects, leading to hypofibrinolysis and hypercoagulability, were found in 43% of patients. This study (82) concluded that von Willebrand's disease, fibrinogen deficiency, antithrombin deficiency, protein C and protein S deficiency, TPA deficiency, and PAI-1 defects played no role in RMS. In a similar study (83) assessing hereditary hemostasis defects in 125 RMS patients, quite different results were noted, and Factor V Leiden mutation was found in 14%.
However, in another study of 50 RMS patients, it was concluded factor V Leiden, Prothrombin G20210A mutation and 5,10-methyltetrahydrofolate reductase mutations were not causes of RMS (84) . Factor V Leiden was discovered by Dahlback et al. in 1993 (85) ; thus, screening has only recently become common. For a summary of this inherited defect, see (85) . As noted above, Kutteh (84) failed to find an association between factor V Leiden and recurrent miscarriage; however, in a recent study (86) , factor V Leiden was found responsible for 48% of recurrent miscarriages. In another study (87) of pregnancy, it was found that although factor V Leiden was responsible for a greater than threefold risk of DVT, there was no association with miscarriage. In another study (88) , however, Factor V Leiden was associated with a high incidence of second trimester miscarriages. Also, two additional studies (89, 90) have clearly shown an association between factor V Leiden mutation and recurrent miscarriages. Thus, the preponderance of current evidence certainly strongly suggests that heterozygous factor V Leiden mutation is a significant risk factor for recurrent miscarriage and increases the risk for miscarriage at least 3.3-fold (86) . Another new common thrombophilic disorder, prothrombin G20210A gene mutation, was described by Poort et al. (91) in 1996. Although Kutteh (84) found no association between this mutation and RMS, another study found an increased risk of recurrent miscarriage of 2.2-fold in women harboring this genetic procoagulant defect (92) . Another newly appreciated hereditary defect that leads to hypercoagulability and thrombosis is 5,10 MTHFR C677T mutation. One study (84) found no association between this defect and recurrent miscarriage; however, another, more recent study (92) has shown a clear association between heterozygosity for this mutation and recurrent miscarriage with those harboring the mutation having a twofold-enhanced risk. Finally, although hypofibrinolysis, in general, has been shown to be associated with recurrent miscarriage (51 ), only recently has the role of PAI-1 elevation and PAI-1 polymorphisms been shown as a cause of recurrent miscarriage syndrome (52). Potential and proposed mechanism(s) of antiphospholipid antibody-induced thrombosis are summarized in Table 7 .
Treatment modalities advocated have been numerous.
Because fetal loss associated with hemorrhagic disorders is thought to come about because of interference with adequate fibrin formation for implantation of the fertilized ovum into the uterine lining, we chose to not use vigorous preconception antithrombotic therapy and to use low dose ASA at 81 mg/d; this may be of theoretical only, in view of the recent report of Sher (93) who used preconception low dose heparin with a high success rate for in vitro fertilization techniques (93) .
However, we remain concerned and continue to advocate low dose ASA as the preconception antithrombotic therapy in most instances (1, 2) . The regimen of postconception addition of fixed low dose porcine mucosal heparin at 5000 U every 12 hours is empirical, but higher doses seem to be associated with bleeding and a lower success rate (94, 95) . However, it may be that even lower doses might suffice. We do not advocate using corticosteroid therapy in this population, based upon the negative experience of others in fetal wastage syndrome, and our own preliminary experience of using steroids, in conjunction with antithrombotics, in patients with antiphospholipid syndrome and other types of thrombosis. In most instances, the corticosteroid use could be shown to lower antiphospholipid antibody titers, but failed to abort thrombotic events (1, 2, 42, 43, (55) (56) (57) . In addition, it is thought that steroid use in patients with APLS may be detrimental (96) .
A variety of treatment programs have been utilized for women with antiphospholipid (anticardiolipin antibodies or lupus anticoagulants) and fetal wastage syndrome; however, many of these studies have studied only very small populations or fail to distinguish between primary or secondary antiphospholipid syndrome in the information provided. Brown (97) reported a 90% failure rate (miscarriage) among untreated women; Perino (98) reports a 93% failure rate in untreated women; and Many (99) reports a 93% failure rate in untreated patients. Lubbe (100) , in a small group of women, noted a successful term pregnancy rate of 80% with use of prednisone and ASA, and a similar success rate with this regimen was noted by Lin (101) . Cowchuck (102) noted a 75% success rate with prednisone alone or ASA alone, but also noted more undesirable effects in the prednisone-treated population. Landy (103) , in a small population, reported a success rate of 90% with either ASA alone or prednisone alone. However, Many (99) only noted a 43% successful term pregnancy rate with ASA and prednisone, and Semprini (104) noted only a 14% success rate with prednisone alone. Several studies have assessed the role of post-conception addition of heparin; however, most have used higher doses than used in our population. Rosove (94) reports a 93% success rate with dose-adjusted subcutaneous heparin, the mean heparin doses being about 25,000 U/d. Kuttah (95) , in a population of 25 patients treated with ASA plus dose-adjusted subcutaneous heparin, noted a success rate of 76%; the mean heparin dose was 26,000 U/d. In Many's (99) study, patients treated with prednisone plus ASA plus heparin at 5000 U twice a day had a better outcome (69%) than did those treated with ASA plus prednisone (43%) or with prednisone alone (7%). Based on our original and current results (1, 2) , it appears that fixed low dose porcine heparin is more effective than the high dose, dose-adjusted regimens, with more than 98% of our RMS population with antiphospholipid syndrome or other prothrombotic propensity having a normal term delivery. It may be that higher doses of heparin somehow contribute to adverse outcomes, such as small periplacental hemorrhages. Parke (105) reports on the combination of low dose heparin used in conjunction with intravenous immunoglobulin (IVIG) . Her success rate, however, was only 27%, suggesting that IVIG has little role in antiphospholipid fetal wastage syndrome. SUMMARY Recurrent miscarriage syndrome and infertility are common problems in the United States, with recurrent miscarriage affecting more than 500,000 women annually. If properly screened through a cost-effective protocol as outlined above, the etiology will be found in almost all women. The most common singular defect in women with RMS is a hemostasis defect, and the most common of these is APLS, if a thorough APLS evaluation is performed. If subgroups are not searched for all three idiotypes, about 24% of patients will be missed. Following APLS, other hereditary and acquired procoagulant defects are also commonly found, if looked for. It is important to appropriately and sequentially evaluate women with RMS, because if an etiology is found, the majority will have positive outcomes with normal term delivery. Hemorrhagic defects are very rare hemostasis causes of RMS, but these also are treatable in many instances and should be looked for in appropriate women. Treatment of the common procoagulant defects consists of preconception low dose ASA at 81 mg/d followed by addition of immediate postconception low dose unfractionated porcine heparin. In our experience, patients with procoagulant defects so treated have a greater than 98% chance of normal term delivery. Low molecular weight heparin may be a suitable alternative, but this is, as yet, unknown.
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